Palvella Therapeutics, Inc. (NASDAQ:PVLA) Receives Average Rating of “Moderate Buy” from Brokerages

Palvella Therapeutics, Inc. (NASDAQ:PVLA) has received a consensus recommendation of “Moderate Buy” from the thirteen research firms that are covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, eleven have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $75.50.

PVLA has been the subject of several recent analyst reports. Canaccord Genuity Group upped their price objective on shares of Palvella Therapeutics from $66.00 to $90.00 and gave the stock a “buy” rating in a research report on Thursday. Raymond James Financial set a $54.00 price objective on shares of Palvella Therapeutics and gave the stock an “outperform” rating in a research report on Tuesday, August 5th. Chardan Capital boosted their target price on Palvella Therapeutics from $60.00 to $73.00 and gave the stock a “buy” rating in a research note on Friday, September 26th. Lifesci Capital started coverage on Palvella Therapeutics in a research note on Monday, August 4th. They set an “outperform” rating and a $90.00 target price for the company. Finally, Oppenheimer started coverage on Palvella Therapeutics in a research note on Tuesday, September 9th. They set an “outperform” rating and a $85.00 target price for the company.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of PVLA. Spire Wealth Management acquired a new position in Palvella Therapeutics during the first quarter worth about $70,000. Strid Group LLC bought a new position in Palvella Therapeutics in the 1st quarter valued at approximately $818,000. Royce & Associates LP bought a new position in Palvella Therapeutics in the 1st quarter valued at approximately $2,002,000. Frazier Life Sciences Management L.P. boosted its position in Palvella Therapeutics by 5.5% during the 1st quarter. Frazier Life Sciences Management L.P. now owns 690,012 shares of the company’s stock worth $19,313,000 after buying an additional 36,120 shares during the period. Finally, AWM Investment Company Inc. bought a new stake in Palvella Therapeutics during the 1st quarter worth approximately $1,943,000. Institutional investors and hedge funds own 40.11% of the company’s stock.

Palvella Therapeutics Stock Down 0.3%

PVLA opened at $69.90 on Friday. Palvella Therapeutics has a twelve month low of $11.17 and a twelve month high of $76.43. The company has a 50-day simple moving average of $54.75 and a 200 day simple moving average of $35.56. The stock has a market capitalization of $773.09 million, a price-to-earnings ratio of -5.78 and a beta of -0.13.

Palvella Therapeutics (NASDAQ:PVLA) last posted its quarterly earnings data on Thursday, August 14th. The company reported ($0.86) earnings per share for the quarter, missing the consensus estimate of ($0.78) by ($0.08). Sell-side analysts anticipate that Palvella Therapeutics will post -3.69 EPS for the current fiscal year.

Palvella Therapeutics Company Profile

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.